STERIS plc $STE Shares Purchased by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC grew its stake in shares of STERIS plc (NYSE:STE) by 149.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,573 shares of the medical equipment provider’s stock after buying an additional 2,737 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in STERIS were worth $1,180,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Mediolanum International Funds Ltd lifted its holdings in STERIS by 9.0% in the 2nd quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after purchasing an additional 5,156 shares in the last quarter. Entropy Technologies LP grew its holdings in shares of STERIS by 282.2% during the second quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after buying an additional 6,718 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of STERIS by 1.7% during the second quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock worth $2,921,827,000 after buying an additional 205,276 shares in the last quarter. Asset Management One Co. Ltd. raised its position in shares of STERIS by 5.4% in the third quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after buying an additional 5,072 shares during the last quarter. Finally, Cerity Partners LLC raised its position in shares of STERIS by 28.8% in the third quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after buying an additional 21,656 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Stock Down 3.4%

Shares of NYSE:STE opened at $230.49 on Friday. The company has a market capitalization of $22.60 billion, a price-to-earnings ratio of 32.15 and a beta of 1.05. The company has a 50 day moving average of $254.37 and a two-hundred day moving average of $251.51. STERIS plc has a 52-week low of $204.90 and a 52-week high of $269.44. The company has a quick ratio of 1.75, a current ratio of 2.48 and a debt-to-equity ratio of 0.26.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a $0.63 dividend. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS’s payout ratio is currently 35.15%.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the completion of the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. This represents a 81.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.07% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on STE shares. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Friday, January 9th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.